<DOC>
	<DOCNO>NCT00002930</DOCNO>
	<brief_summary>RATIONALE : Imaging procedure , fludeoxyglucose F 18 positron emission tomography ( PET ) scan , may improve ability detect lung esophageal cancer recurrence . PURPOSE : Phase II/III trial study effectiveness fludeoxyglucose F 18 PET scan measure response induction chemotherapy patient esophageal lung cancer may remove surgery .</brief_summary>
	<brief_title>PET Scan Patients With Lung Esophageal Cancers That May Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether whole body fludeoxyglucose F 18 ( F-18 2-fluoro-2-deoxy-D-glucose ; FDG ) positron emission tomography ( PET ) quantitate response induction ( preoperative ) chemotherapy patient esophageal non-small cell lung cancer ( NSCLC ) correlate change PET scan image surgical staging , frequency complete resection , disease-free survival , overall survival . II . Correlate PET scan result multiple conventional complementary imaging modality thoracic and/or abdominal CT , bone scan , cranial MRI . III . Evaluate use PET scan uncover disease site undetected current imaging modality . OUTLINE : This nonrandomized study . The choice chemotherapeutic regimen discretion medical oncologist . If tumor resectable treatment chemotherapy , patient undergoes appropriate resection define thoracic surgeon . All patient positron emission tomography ( PET ) scan do within 2 week first dose chemotherapy 2-3 week third fourth dose chemotherapy . Patients ask eat drink 6 hour come hospital PET scan . They administer injection solution fluorodeoxyglucose F 18 ( FDG ) undergo PET scan . PROJECTED ACCRUAL : An estimated 75 patient ( 50 lung cancer 25 esophageal cancer patient ) accrue protocol 24-30 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm esophageal nonsmall cell lung carcinoma Esophageal cancer : Biopsy proven esophageal carcinoma consider acceptable curative esophageal resection Lung cancer : Stages IAIIIB , T ( ) N ( ) M0 disease without pleural effusion , constitute locally advanced lung cancer Must candidate induction chemotherapy follow surgical resection PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : WBC least 4,000/mm3 Platelet count least 160,000/mm3 Hepatic : Bilirubin great 1.0 mg/dL Renal : Creatinine great 1.5 mg/dL Creatinine clearance great 65 mL/min Other : Not pregnant Adequate contraception require fertile female patient PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : No prior surgical mediastinal stag prior mediastinoscopy Chamberlain procedure See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage I esophageal cancer</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>